The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Live Attenuated Measles Vaccine Market Research Report 2025

Global Live Attenuated Measles Vaccine Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1728279

No of Pages : 104

Ask Your Query

Synopsis
Highlights
The global Live Attenuated Measles Vaccine market is projected to reach US$ million by 2028 from an estimated US$ million in 2022, at a CAGR of % during 2023 and 2028.
The major global manufacturers of Live Attenuated Measles Vaccine include GSK, Sanofi-Pasteur, Merck, Pfizer, Serum Institute of India, Novartis, Emergent Biosolutions, Bavarian Nordic and Medimmune, etc. In 2021, the world's top three vendors accounted for approximately % of the revenue.
Considering the economic change due to COVID-19 and Russia-Ukraine War Influence, Liquid, which accounted for % of the global market of Live Attenuated Measles Vaccine in 2021, is expected to reach million US$ by 2028, growing at a revised CAGR of % from 2022 to 2028.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Live Attenuated Measles Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Live Attenuated Measles Vaccine.
The Live Attenuated Measles Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Live Attenuated Measles Vaccine market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Live Attenuated Measles Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.

Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Some of the prominent players reviewed in the research report include:

  • GSK
  • Sanofi-Pasteur
  • Merck
  • Pfizer
  • Serum Institute of India
  • Novartis
  • Emergent Biosolutions
  • Bavarian Nordic
  • Medimmune
  • Johnson & Johnson
  • CSL Limited
  • Changchun Qijian Biological Products Co., Ltd
  • Beijing Institute of Biological Products Co., Ltd
  • Wuhan Institute of Biological Products Co., Ltd
  • Shanghai Institute of Biological Products Co., Ltd
  • Lanzhou Institute of Biological Products Co., Ltd

Product Type Insights
Global markets are presented by Live Attenuated Measles Vaccine type, along with growth forecasts through 2028. Estimates on sales and revenue are based on the price in the supply chain at which the Live Attenuated Measles Vaccine are procured by the manufacturers.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows sales and revenue data by type, and during the historical period (2017-2022) and forecast period (2023-2028).

Live Attenuated Measles Vaccine segment by Type

  • Liquid
  • Powder

Application Insights
This report has provided the market size (sales and revenue data) by application, during the historical period (2017-2022) and forecast period (2023-2028).
This report also outlines the market trends of each segment and consumer behaviors impacting the Live Attenuated Measles Vaccine market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Live Attenuated Measles Vaccine market.

Live Attenuated Measles Vaccine segment by Application

  • Hospital
  • Clinic

Regional Outlook
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2017-2028.
The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2021 because of the base year, with estimates for 2022 and forecast revenue for 2028.

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
  • Latin America (Mexico, Brazil, Argentina, Colombia)

Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Live Attenuated Measles Vaccine market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

Reasons to Buy This Report

  • This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Live Attenuated Measles Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
  • This report will help stakeholders to understand the global industry status and trends of Live Attenuated Measles Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
  • This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
  • This report stays updated with novel technology integration, features, and the latest developments in the market
  • This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Live Attenuated Measles Vaccine industry.
  • This report helps stakeholders to gain insights into which regions to target globally
  • This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Live Attenuated Measles Vaccine.
  • This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Live Attenuated Measles Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Live Attenuated Measles Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Analysis of sales channel, distributors and customers
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: sales and revenue forecast, global and regional, by Type and by Application. It provides a quantitative analysis of the market size and development potential of each market segment in the next six years.
Chapter 11: The main points and conclusions of the report.

Index

1 Live Attenuated Measles Vaccine Market Overview
1.1 Product Overview and Scope of Live Attenuated Measles Vaccine
1.2 Live Attenuated Measles Vaccine Segment by Type
1.2.1 Global Live Attenuated Measles Vaccine Sales Growth Rate Comparison by Type (2022-2028)
1.2.2 Liquid
1.2.3 Powder
1.3 Live Attenuated Measles Vaccine Segment by Application
1.3.1 Global Live Attenuated Measles Vaccine Sales Comparison by Application: (2022-2028)
1.3.2 Hospital
1.3.3 Clinic
1.4 Global Live Attenuated Measles Vaccine Market Size Estimates and Forecasts
1.4.1 Global Live Attenuated Measles Vaccine Revenue 2017-2028
1.4.2 Global Live Attenuated Measles Vaccine Sales 2017-2028
1.4.3 Live Attenuated Measles Vaccine Market Size by Region: 2017 Versus 2021 Versus 2028
2 Live Attenuated Measles Vaccine Market Competition by Manufacturers
2.1 Global Live Attenuated Measles Vaccine Sales Market Share by Manufacturers (2017-2022)
2.2 Global Live Attenuated Measles Vaccine Revenue Market Share by Manufacturers (2017-2022)
2.3 Global Live Attenuated Measles Vaccine Average Price by Manufacturers (2017-2022)
2.4 Manufacturers Live Attenuated Measles Vaccine Manufacturing Sites, Area Served, Product Type
2.5 Live Attenuated Measles Vaccine Market Competitive Situation and Trends
2.5.1 Live Attenuated Measles Vaccine Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Live Attenuated Measles Vaccine Players Market Share by Revenue
2.5.3 Global Live Attenuated Measles Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Live Attenuated Measles Vaccine Retrospective Market Scenario by Region
3.1 Global Live Attenuated Measles Vaccine Retrospective Market Scenario in Sales by Region: 2017-2022
3.2 Global Live Attenuated Measles Vaccine Retrospective Market Scenario in Revenue by Region: 2017-2022
3.3 North America Live Attenuated Measles Vaccine Market Facts & Figures by Country
3.3.1 North America Live Attenuated Measles Vaccine Sales by Country
3.3.2 North America Live Attenuated Measles Vaccine Revenue by Country
3.3.3 United States
3.3.4 Canada
3.4 Europe Live Attenuated Measles Vaccine Market Facts & Figures by Country
3.4.1 Europe Live Attenuated Measles Vaccine Sales by Country
3.4.2 Europe Live Attenuated Measles Vaccine Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Live Attenuated Measles Vaccine Market Facts & Figures by Region
3.5.1 Asia Pacific Live Attenuated Measles Vaccine Sales by Region
3.5.2 Asia Pacific Live Attenuated Measles Vaccine Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 China Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.6 Latin America Live Attenuated Measles Vaccine Market Facts & Figures by Country
3.6.1 Latin America Live Attenuated Measles Vaccine Sales by Country
3.6.2 Latin America Live Attenuated Measles Vaccine Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.6.6 Colombia
3.7 Middle East and Africa Live Attenuated Measles Vaccine Market Facts & Figures by Country
3.7.1 Middle East and Africa Live Attenuated Measles Vaccine Sales by Country
3.7.2 Middle East and Africa Live Attenuated Measles Vaccine Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global Live Attenuated Measles Vaccine Historic Market Analysis by Type
4.1 Global Live Attenuated Measles Vaccine Sales Market Share by Type (2017-2022)
4.2 Global Live Attenuated Measles Vaccine Revenue Market Share by Type (2017-2022)
4.3 Global Live Attenuated Measles Vaccine Price by Type (2017-2022)
5 Global Live Attenuated Measles Vaccine Historic Market Analysis by Application
5.1 Global Live Attenuated Measles Vaccine Sales Market Share by Application (2017-2022)
5.2 Global Live Attenuated Measles Vaccine Revenue Market Share by Application (2017-2022)
5.3 Global Live Attenuated Measles Vaccine Price by Application (2017-2022)
6 Key Companies Profiled
6.1 GSK
6.1.1 GSK Corporation Information
6.1.2 GSK Description and Business Overview
6.1.3 GSK Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2017-2022)
6.1.4 GSK Live Attenuated Measles Vaccine Product Portfolio
6.1.5 GSK Recent Developments/Updates
6.2 Sanofi-Pasteur
6.2.1 Sanofi-Pasteur Corporation Information
6.2.2 Sanofi-Pasteur Description and Business Overview
6.2.3 Sanofi-Pasteur Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2017-2022)
6.2.4 Sanofi-Pasteur Live Attenuated Measles Vaccine Product Portfolio
6.2.5 Sanofi-Pasteur Recent Developments/Updates
6.3 Merck
6.3.1 Merck Corporation Information
6.3.2 Merck Description and Business Overview
6.3.3 Merck Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2017-2022)
6.3.4 Merck Live Attenuated Measles Vaccine Product Portfolio
6.3.5 Merck Recent Developments/Updates
6.4 Pfizer
6.4.1 Pfizer Corporation Information
6.4.2 Pfizer Description and Business Overview
6.4.3 Pfizer Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Pfizer Live Attenuated Measles Vaccine Product Portfolio
6.4.5 Pfizer Recent Developments/Updates
6.5 Serum Institute of India
6.5.1 Serum Institute of India Corporation Information
6.5.2 Serum Institute of India Description and Business Overview
6.5.3 Serum Institute of India Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2017-2022)
6.5.4 Serum Institute of India Live Attenuated Measles Vaccine Product Portfolio
6.5.5 Serum Institute of India Recent Developments/Updates
6.6 Novartis
6.6.1 Novartis Corporation Information
6.6.2 Novartis Description and Business Overview
6.6.3 Novartis Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2017-2022)
6.6.4 Novartis Live Attenuated Measles Vaccine Product Portfolio
6.6.5 Novartis Recent Developments/Updates
6.7 Emergent Biosolutions
6.6.1 Emergent Biosolutions Corporation Information
6.6.2 Emergent Biosolutions Description and Business Overview
6.6.3 Emergent Biosolutions Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Emergent Biosolutions Live Attenuated Measles Vaccine Product Portfolio
6.7.5 Emergent Biosolutions Recent Developments/Updates
6.8 Bavarian Nordic
6.8.1 Bavarian Nordic Corporation Information
6.8.2 Bavarian Nordic Description and Business Overview
6.8.3 Bavarian Nordic Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2017-2022)
6.8.4 Bavarian Nordic Live Attenuated Measles Vaccine Product Portfolio
6.8.5 Bavarian Nordic Recent Developments/Updates
6.9 Medimmune
6.9.1 Medimmune Corporation Information
6.9.2 Medimmune Description and Business Overview
6.9.3 Medimmune Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2017-2022)
6.9.4 Medimmune Live Attenuated Measles Vaccine Product Portfolio
6.9.5 Medimmune Recent Developments/Updates
6.10 Johnson & Johnson
6.10.1 Johnson & Johnson Corporation Information
6.10.2 Johnson & Johnson Description and Business Overview
6.10.3 Johnson & Johnson Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2017-2022)
6.10.4 Johnson & Johnson Live Attenuated Measles Vaccine Product Portfolio
6.10.5 Johnson & Johnson Recent Developments/Updates
6.11 CSL Limited
6.11.1 CSL Limited Corporation Information
6.11.2 CSL Limited Live Attenuated Measles Vaccine Description and Business Overview
6.11.3 CSL Limited Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2017-2022)
6.11.4 CSL Limited Live Attenuated Measles Vaccine Product Portfolio
6.11.5 CSL Limited Recent Developments/Updates
6.12 Changchun Qijian Biological Products Co., Ltd
6.12.1 Changchun Qijian Biological Products Co., Ltd Corporation Information
6.12.2 Changchun Qijian Biological Products Co., Ltd Live Attenuated Measles Vaccine Description and Business Overview
6.12.3 Changchun Qijian Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2017-2022)
6.12.4 Changchun Qijian Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio
6.12.5 Changchun Qijian Biological Products Co., Ltd Recent Developments/Updates
6.13 Beijing Institute of Biological Products Co., Ltd
6.13.1 Beijing Institute of Biological Products Co., Ltd Corporation Information
6.13.2 Beijing Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Description and Business Overview
6.13.3 Beijing Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2017-2022)
6.13.4 Beijing Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio
6.13.5 Beijing Institute of Biological Products Co., Ltd Recent Developments/Updates
6.14 Wuhan Institute of Biological Products Co., Ltd
6.14.1 Wuhan Institute of Biological Products Co., Ltd Corporation Information
6.14.2 Wuhan Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Description and Business Overview
6.14.3 Wuhan Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2017-2022)
6.14.4 Wuhan Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio
6.14.5 Wuhan Institute of Biological Products Co., Ltd Recent Developments/Updates
6.15 Shanghai Institute of Biological Products Co., Ltd
6.15.1 Shanghai Institute of Biological Products Co., Ltd Corporation Information
6.15.2 Shanghai Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Description and Business Overview
6.15.3 Shanghai Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2017-2022)
6.15.4 Shanghai Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio
6.15.5 Shanghai Institute of Biological Products Co., Ltd Recent Developments/Updates
6.16 Lanzhou Institute of Biological Products Co., Ltd
6.16.1 Lanzhou Institute of Biological Products Co., Ltd Corporation Information
6.16.2 Lanzhou Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Description and Business Overview
6.16.3 Lanzhou Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2017-2022)
6.16.4 Lanzhou Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio
6.16.5 Lanzhou Institute of Biological Products Co., Ltd Recent Developments/Updates
7 Live Attenuated Measles Vaccine Manufacturing Cost Analysis
7.1 Live Attenuated Measles Vaccine Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Live Attenuated Measles Vaccine
7.4 Live Attenuated Measles Vaccine Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Live Attenuated Measles Vaccine Distributors List
8.3 Live Attenuated Measles Vaccine Customers
9 Live Attenuated Measles Vaccine Market Dynamics
9.1 Live Attenuated Measles Vaccine Industry Trends
9.2 Live Attenuated Measles Vaccine Market Drivers
9.3 Live Attenuated Measles Vaccine Market Challenges
9.4 Live Attenuated Measles Vaccine Market Restraints
10 Global Market Forecast
10.1 Live Attenuated Measles Vaccine Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Live Attenuated Measles Vaccine by Type (2023-2028)
10.1.2 Global Forecasted Revenue of Live Attenuated Measles Vaccine by Type (2023-2028)
10.2 Live Attenuated Measles Vaccine Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Live Attenuated Measles Vaccine by Application (2023-2028)
10.2.2 Global Forecasted Revenue of Live Attenuated Measles Vaccine by Application (2023-2028)
10.3 Live Attenuated Measles Vaccine Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Live Attenuated Measles Vaccine by Region (2023-2028)
10.3.2 Global Forecasted Revenue of Live Attenuated Measles Vaccine by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer

List of Tables

List of Tables
Table 1. Global Live Attenuated Measles Vaccine Sales Growth Rate Comparison by Type (2022-2028) & (K Units) & (US$ Million)
Table 2. Global Live Attenuated Measles Vaccine Sales Growth Rate Comparison by Application (2022-2028) & (K Units) & (US$ Million)
Table 3. Global Live Attenuated Measles Vaccine Market Size by Region (US$ Million) (2017 VS 2021 VS 2028)
Table 4. Global Live Attenuated Measles Vaccine Market Competitive Situation by Manufacturers in 2021
Table 5. Global Live Attenuated Measles Vaccine Sales (K Units) of Key Manufacturers (2017-2022)
Table 6. Global Live Attenuated Measles Vaccine Sales Market Share by Manufacturers (2017-2022)
Table 7. Global Live Attenuated Measles Vaccine Revenue (US$ Million) by Manufacturers (2017-2022)
Table 8. Global Live Attenuated Measles Vaccine Revenue Share by Manufacturers (2017-2022)
Table 9. Global Market Live Attenuated Measles Vaccine Average Price (US$/Unit) of Key Manufacturers (2017-2022)
Table 10. Manufacturers Live Attenuated Measles Vaccine Manufacturing Sites and Area Served
Table 11. Manufacturers Live Attenuated Measles Vaccine Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Live Attenuated Measles Vaccine by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Live Attenuated Measles Vaccine as of 2021)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Live Attenuated Measles Vaccine Sales by Region (2017-2022) & (K Units)
Table 16. Global Live Attenuated Measles Vaccine Sales Market Share by Region (2017-2022)
Table 17. Global Live Attenuated Measles Vaccine Revenue by Region (2017-2022) & (US$ Million)
Table 18. Global Live Attenuated Measles Vaccine Revenue Market Share by Region (2017-2022)
Table 19. North America Live Attenuated Measles Vaccine Sales by Country (2017-2022) & (K Units)
Table 20. North America Live Attenuated Measles Vaccine Sales Market Share by Country (2017-2022)
Table 21. North America Live Attenuated Measles Vaccine Revenue by Country (2017-2022) & (US$ Million)
Table 22. North America Live Attenuated Measles Vaccine Revenue Market Share by Country (2017-2022)
Table 23. Europe Live Attenuated Measles Vaccine Sales by Country (2017-2022) & (K Units)
Table 24. Europe Live Attenuated Measles Vaccine Sales Market Share by Country (2017-2022)
Table 25. Europe Live Attenuated Measles Vaccine Revenue by Country (2017-2022) & (US$ Million)
Table 26. Europe Live Attenuated Measles Vaccine Revenue Market Share by Country (2017-2022)
Table 27. Asia Pacific Live Attenuated Measles Vaccine Sales by Region (2017-2022) & (K Units)
Table 28. Asia Pacific Live Attenuated Measles Vaccine Sales Market Share by Region (2017-2022)
Table 29. Asia Pacific Live Attenuated Measles Vaccine Revenue by Region (2017-2022) & (US$ Million)
Table 30. Asia Pacific Live Attenuated Measles Vaccine Revenue Market Share by Region (2017-2022)
Table 31. Latin America Live Attenuated Measles Vaccine Sales by Country (2017-2022) & (K Units)
Table 32. Latin America Live Attenuated Measles Vaccine Sales Market Share by Country (2017-2022)
Table 33. Latin America Live Attenuated Measles Vaccine Revenue by Country (2017-2022) & (US$ Million)
Table 34. Latin America Live Attenuated Measles Vaccine Revenue Market Share by Country (2017-2022)
Table 35. Middle East and Africa Live Attenuated Measles Vaccine Sales by Country (2017-2022) & (K Units)
Table 36. Middle East and Africa Live Attenuated Measles Vaccine Sales Market Share by Country (2017-2022)
Table 37. Middle East and Africa Live Attenuated Measles Vaccine Revenue by Country (2017-2022) & (US$ Million)
Table 38. Middle East and Africa Live Attenuated Measles Vaccine Revenue Market Share by Country (2017-2022)
Table 39. Global Live Attenuated Measles Vaccine Sales by Type (2017-2022) & (K Units)
Table 40. Global Live Attenuated Measles Vaccine Sales Market Share by Type (2017-2022)
Table 41. Global Live Attenuated Measles Vaccine Revenue by Type (2017-2022) & (US$ Million)
Table 42. Global Live Attenuated Measles Vaccine Revenue Share by Type (2017-2022)
Table 43. Global Live Attenuated Measles Vaccine Price by Type (2017-2022) & (US$/Unit)
Table 44. Global Live Attenuated Measles Vaccine Sales (K Units) by Application (2017-2022)
Table 45. Global Live Attenuated Measles Vaccine Sales Market Share by Application (2017-2022)
Table 46. Global Live Attenuated Measles Vaccine Revenue by Application (2017-2022) & (US$ Million)
Table 47. Global Live Attenuated Measles Vaccine Revenue Share by Application (2017-2022)
Table 48. Global Live Attenuated Measles Vaccine Price by Application (2017-2022) & (US$/Unit)
Table 49. GSK Corporation Information
Table 50. GSK Description and Business Overview
Table 51. GSK Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 52. GSK Live Attenuated Measles Vaccine Product
Table 53. GSK Recent Developments/Updates
Table 54. Sanofi-Pasteur Corporation Information
Table 55. Sanofi-Pasteur Description and Business Overview
Table 56. Sanofi-Pasteur Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 57. Sanofi-Pasteur Live Attenuated Measles Vaccine Product
Table 58. Sanofi-Pasteur Recent Developments/Updates
Table 59. Merck Corporation Information
Table 60. Merck Description and Business Overview
Table 61. Merck Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 62. Merck Live Attenuated Measles Vaccine Product
Table 63. Merck Recent Developments/Updates
Table 64. Pfizer Corporation Information
Table 65. Pfizer Description and Business Overview
Table 66. Pfizer Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 67. Pfizer Live Attenuated Measles Vaccine Product
Table 68. Pfizer Recent Developments/Updates
Table 69. Serum Institute of India Corporation Information
Table 70. Serum Institute of India Description and Business Overview
Table 71. Serum Institute of India Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 72. Serum Institute of India Live Attenuated Measles Vaccine Product
Table 73. Serum Institute of India Recent Developments/Updates
Table 74. Novartis Corporation Information
Table 75. Novartis Description and Business Overview
Table 76. Novartis Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 77. Novartis Live Attenuated Measles Vaccine Product
Table 78. Novartis Recent Developments/Updates
Table 79. Emergent Biosolutions Corporation Information
Table 80. Emergent Biosolutions Description and Business Overview
Table 81. Emergent Biosolutions Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 82. Emergent Biosolutions Live Attenuated Measles Vaccine Product
Table 83. Emergent Biosolutions Recent Developments/Updates
Table 84. Bavarian Nordic Corporation Information
Table 85. Bavarian Nordic Description and Business Overview
Table 86. Bavarian Nordic Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 87. Bavarian Nordic Live Attenuated Measles Vaccine Product
Table 88. Bavarian Nordic Recent Developments/Updates
Table 89. Medimmune Corporation Information
Table 90. Medimmune Description and Business Overview
Table 91. Medimmune Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 92. Medimmune Live Attenuated Measles Vaccine Product
Table 93. Medimmune Recent Developments/Updates
Table 94. Johnson & Johnson Corporation Information
Table 95. Johnson & Johnson Description and Business Overview
Table 96. Johnson & Johnson Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 97. Johnson & Johnson Live Attenuated Measles Vaccine Product
Table 98. Johnson & Johnson Recent Developments/Updates
Table 99. CSL Limited Corporation Information
Table 100. CSL Limited Description and Business Overview
Table 101. CSL Limited Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 102. CSL Limited Live Attenuated Measles Vaccine Product
Table 103. CSL Limited Recent Developments/Updates
Table 104. Changchun Qijian Biological Products Co., Ltd Corporation Information
Table 105. Changchun Qijian Biological Products Co., Ltd Description and Business Overview
Table 106. Changchun Qijian Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 107. Changchun Qijian Biological Products Co., Ltd Live Attenuated Measles Vaccine Product
Table 108. Changchun Qijian Biological Products Co., Ltd Recent Developments/Updates
Table 109. Beijing Institute of Biological Products Co., Ltd Corporation Information
Table 110. Beijing Institute of Biological Products Co., Ltd Description and Business Overview
Table 111. Beijing Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 112. Beijing Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product
Table 113. Beijing Institute of Biological Products Co., Ltd Recent Developments/Updates
Table 114. Wuhan Institute of Biological Products Co., Ltd Corporation Information
Table 115. Wuhan Institute of Biological Products Co., Ltd Description and Business Overview
Table 116. Wuhan Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 117. Wuhan Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product
Table 118. Wuhan Institute of Biological Products Co., Ltd Recent Developments/Updates
Table 119. Shanghai Institute of Biological Products Co., Ltd Corporation Information
Table 120. Shanghai Institute of Biological Products Co., Ltd Description and Business Overview
Table 121. Shanghai Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 122. Shanghai Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product
Table 123. Shanghai Institute of Biological Products Co., Ltd Recent Developments/Updates
Table 124. Lanzhou Institute of Biological Products Co., Ltd Corporation Information
Table 125. Lanzhou Institute of Biological Products Co., Ltd Description and Business Overview
Table 126. Lanzhou Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 127. Lanzhou Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product
Table 128. Lanzhou Institute of Biological Products Co., Ltd Recent Developments/Updates
Table 129. Production Base and Market Concentration Rate of Raw Material
Table 130. Key Suppliers of Raw Materials
Table 131. Live Attenuated Measles Vaccine Distributors List
Table 132. Live Attenuated Measles Vaccine Customers List
Table 133. Live Attenuated Measles Vaccine Market Trends
Table 134. Live Attenuated Measles Vaccine Market Drivers
Table 135. Live Attenuated Measles Vaccine Market Challenges
Table 136. Live Attenuated Measles Vaccine Market Restraints
Table 137. Global Live Attenuated Measles Vaccine Sales Forecast by Type (2023-2028) & (K Units)
Table 138. Global Live Attenuated Measles Vaccine Sales Market Share Forecast by Type (2023-2028)
Table 139. Global Live Attenuated Measles Vaccine Revenue Forecast by Type (2023-2028) & (US$ Million)
Table 140. Global Live Attenuated Measles Vaccine Revenue Market Share Forecast by Type (2023-2028)
Table 141. Global Live Attenuated Measles Vaccine Sales Forecast by Application (2023-2028) & (K Units)
Table 142. Global Live Attenuated Measles Vaccine Sales Market Share Forecast by Application (2023-2028)
Table 143. Global Live Attenuated Measles Vaccine Revenue Forecast by Application (2023-2028) & (US$ Million)
Table 144. Global Live Attenuated Measles Vaccine Revenue Market Share Forecast by Application (2023-2028)
Table 145. Global Live Attenuated Measles Vaccine Sales Forecast by Region (2023-2028) & (K Units)
Table 146. Global Live Attenuated Measles Vaccine Sales Market Share Forecast by Region (2023-2028)
Table 147. Global Live Attenuated Measles Vaccine Revenue Forecast by Region (2023-2028) & (US$ Million)
Table 148. Global Live Attenuated Measles Vaccine Revenue Market Share Forecast by Region (2023-2028)
Table 149. Research Programs/Design for This Report
Table 150. Key Data Information from Secondary Sources
Table 151. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Live Attenuated Measles Vaccine
Figure 2. Global Live Attenuated Measles Vaccine Market Share by Type in 2021 & 2028
Figure 3. Liquid Product Picture
Figure 4. Powder Product Picture
Figure 5. Global Live Attenuated Measles Vaccine Market Share by Application in 2021 & 2028
Figure 6. Hospital
Figure 7. Clinic
Figure 8. Global Live Attenuated Measles Vaccine Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 9. Global Live Attenuated Measles Vaccine Market Size (2017-2028) & (US$ Million)
Figure 10. Global Live Attenuated Measles Vaccine Sales (2017-2028) & (K Units)
Figure 11. Live Attenuated Measles Vaccine Sales Share by Manufacturers in 2021
Figure 12. Global Live Attenuated Measles Vaccine Revenue Share by Manufacturers in 2021
Figure 13. The Global 5 and 10 Largest Live Attenuated Measles Vaccine Players: Market Share by Revenue in 2021
Figure 14. Live Attenuated Measles Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021
Figure 15. Global Live Attenuated Measles Vaccine Sales Market Share by Region (2017-2022)
Figure 16. Global Live Attenuated Measles Vaccine Sales Market Share by Region in 2021
Figure 17. Global Live Attenuated Measles Vaccine Revenue Market Share by Region (2017-2022)
Figure 18. Global Live Attenuated Measles Vaccine Revenue Market Share by Region in 2021
Figure 19. United States Live Attenuated Measles Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 20. Canada Live Attenuated Measles Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 21. Germany Live Attenuated Measles Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 22. France Live Attenuated Measles Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 23. U.K. Live Attenuated Measles Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 24. Italy Live Attenuated Measles Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 25. Russia Live Attenuated Measles Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 26. China Live Attenuated Measles Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 27. Japan Live Attenuated Measles Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 28. South Korea Live Attenuated Measles Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 29. India Live Attenuated Measles Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 30. Australia Live Attenuated Measles Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 31. China Taiwan Live Attenuated Measles Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 32. Indonesia Live Attenuated Measles Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 33. Thailand Live Attenuated Measles Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 34. Malaysia Live Attenuated Measles Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 35. Mexico Live Attenuated Measles Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 36. Brazil Live Attenuated Measles Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 37. Argentina Live Attenuated Measles Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 38. Colombia Live Attenuated Measles Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 39. Turkey Live Attenuated Measles Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 40. Saudi Arabia Live Attenuated Measles Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 41. UAE Live Attenuated Measles Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 42. Sales Market Share of Live Attenuated Measles Vaccine by Type (2017-2022)
Figure 43. Manufacturing Cost Structure of Live Attenuated Measles Vaccine
Figure 44. Manufacturing Process Analysis of Live Attenuated Measles Vaccine
Figure 45. Live Attenuated Measles Vaccine Industrial Chain Analysis
Figure 46. Channels of Distribution
Figure 47. Distributors Profiles
Figure 48. Bottom-up and Top-down Approaches for This Report
Figure 49. Data Triangulation
Figure 50. Key Executives Interviewed

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock